Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study.
Vincent Launay-Vacher
Research Funding - Amgen; Bayer Schering Pharma; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Fresenius Biotech; Gilead Sciences; Ipsen; Janssen-Cilag; LEO Pharma
Nicolas Janus
Consultant or Advisory Role - Pfizer
Honoraria - Fresenius Biotech; Roche
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar; Roche
Philippe Beuzeboc
No relevant relationships to disclose
Catherine Daniel
No relevant relationships to disclose
Joseph Gligorov
Consultant or Advisory Role - Roche; Teva
Frédéric Selle
No relevant relationships to disclose
Francois Goldwasser
Consultant or Advisory Role - Roche
Honoraria - Roche
Olivier Mir
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche; SERVIER
Research Funding - Pfizer
Jean-Philippe Spano
Consultant or Advisory Role - Amgen; Cephalon; GlaxoSmithKline; LEO Pharma; Merck Serono; MSD; Roche; Sanofi ; Teva
Jean Christophe Thery
No relevant relationships to disclose
Jean-Baptiste Rey
Honoraria - Amgen; Archimedes; Baxter ; B-Braun; Boehringer Ingelheim; Bristol-Myers Squibb; Fresenius Kabi; Helsinn Healthcare; Idis; LEO Pharma; Merck; Merck Serono; Mundipharma; Pfizer; Roche; Sandoz
Christelle Jouannaud
No relevant relationships to disclose
Jean F. Morere
No relevant relationships to disclose
Stephane Oudard
Honoraria - Bayer; Novartis; Pfizer; Sanofi
Florian Scotte
No relevant relationships to disclose
Michel Azizi
No relevant relationships to disclose
Richard Dorent
No relevant relationships to disclose
Gilbert Deray
No relevant relationships to disclose